drugset / Trial / NCT00795821

A Study in Adult Patients With Major Depressive Disorder

NCT00795821

Phase 2/3 Completed 495 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess whether LY2216684 is superior to placebo in the treatment of adult patients with major depressive disorder.

Timeline

Start
2008-12
Primary completion
2010-02
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject edivoxetine Small molecule 6 mg
Subject edivoxetine Small molecule 9 mg
Subject edivoxetine Small molecule 12 mg
Subject edivoxetine Small molecule 18 mg